1. Home
  2. RIGL vs SANA Comparison

RIGL vs SANA Comparison

Compare RIGL & SANA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RIGL
  • SANA
  • Stock Information
  • Founded
  • RIGL 1996
  • SANA 2018
  • Country
  • RIGL United States
  • SANA United States
  • Employees
  • RIGL N/A
  • SANA N/A
  • Industry
  • RIGL Biotechnology: Pharmaceutical Preparations
  • SANA Medicinal Chemicals and Botanical Products
  • Sector
  • RIGL Health Care
  • SANA Health Care
  • Exchange
  • RIGL Nasdaq
  • SANA Nasdaq
  • Market Cap
  • RIGL 486.4M
  • SANA 522.4M
  • IPO Year
  • RIGL 2000
  • SANA 2021
  • Fundamental
  • Price
  • RIGL $21.81
  • SANA $2.92
  • Analyst Decision
  • RIGL Buy
  • SANA Strong Buy
  • Analyst Count
  • RIGL 5
  • SANA 4
  • Target Price
  • RIGL $34.80
  • SANA $13.00
  • AVG Volume (30 Days)
  • RIGL 347.9K
  • SANA 14.7M
  • Earning Date
  • RIGL 03-04-2025
  • SANA 02-27-2025
  • Dividend Yield
  • RIGL N/A
  • SANA N/A
  • EPS Growth
  • RIGL N/A
  • SANA N/A
  • EPS
  • RIGL 0.22
  • SANA N/A
  • Revenue
  • RIGL $157,374,000.00
  • SANA N/A
  • Revenue This Year
  • RIGL $51.34
  • SANA N/A
  • Revenue Next Year
  • RIGL $15.75
  • SANA N/A
  • P/E Ratio
  • RIGL $98.50
  • SANA N/A
  • Revenue Growth
  • RIGL 21.65
  • SANA N/A
  • 52 Week Low
  • RIGL $7.48
  • SANA $1.52
  • 52 Week High
  • RIGL $29.82
  • SANA $12.00
  • Technical
  • Relative Strength Index (RSI)
  • RIGL 64.53
  • SANA 53.45
  • Support Level
  • RIGL $17.28
  • SANA $3.05
  • Resistance Level
  • RIGL $18.25
  • SANA $3.86
  • Average True Range (ATR)
  • RIGL 1.37
  • SANA 0.66
  • MACD
  • RIGL 0.65
  • SANA 0.12
  • Stochastic Oscillator
  • RIGL 99.68
  • SANA 24.22

About RIGL Rigel Pharmaceuticals Inc.

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

About SANA Sana Biotechnology Inc.

Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 among others.

Share on Social Networks: